James D. Phelan

6.0k total citations · 1 hit paper
51 papers, 1.7k citations indexed

About

James D. Phelan is a scholar working on Pathology and Forensic Medicine, Genetics and Immunology. According to data from OpenAlex, James D. Phelan has authored 51 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pathology and Forensic Medicine, 21 papers in Genetics and 20 papers in Immunology. Recurrent topics in James D. Phelan's work include Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Immune Cell Function and Interaction (13 papers). James D. Phelan is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Immune Cell Function and Interaction (13 papers). James D. Phelan collaborates with scholars based in United States, Canada and Germany. James D. Phelan's co-authors include Louis M. Staudt, Ryan M. Young, Wyndham H. Wilson, Arthur L. Shaffer, George W. Wright, Roland Schmitz, Da Wei Huang, Sandrine Roulland, Calvin A. Johnson and David W. Scott and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

James D. Phelan

47 papers receiving 1.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications

2020 583 citations George W. Wright, Da Wei Huang et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James D. Phelan United States	19	866	642	519	490	423	51	1.7k
Holger Nückel Germany	27	625 0.7×	426 0.7×	535 1.0×	749 1.5×	810 1.9×	59	1.9k
Daniel J. Hodson United Kingdom	18	513 0.6×	404 0.6×	635 1.2×	352 0.7×	290 0.7×	45	1.4k
Massimo Degan Italy	24	900 1.0×	603 0.9×	467 0.9×	826 1.7×	764 1.8×	67	1.9k
Outi Kuittinen Finland	23	1.3k 1.5×	848 1.3×	309 0.6×	393 0.8×	526 1.2×	104	2.0k
Roberta Pacini Italy	15	882 1.0×	567 0.9×	601 1.2×	535 1.1×	520 1.2×	20	1.9k
Endi Wang United States	24	801 0.9×	546 0.9×	557 1.1×	218 0.4×	440 1.0×	127	2.0k
Abel Sánchez‐Aguilera Spain	21	508 0.6×	646 1.0×	1.0k 1.9×	485 1.0×	564 1.3×	31	2.2k
Inga Vater Germany	21	701 0.8×	377 0.6×	594 1.1×	324 0.7×	315 0.7×	35	1.6k
Nathalie Gachard France	18	565 0.7×	463 0.7×	311 0.6×	397 0.8×	354 0.8×	57	1.3k
Alessandra Stacchini Italy	26	499 0.6×	558 0.9×	508 1.0×	638 1.3×	637 1.5×	76	1.9k

Countries citing papers authored by James D. Phelan

Since Specialization

Citations

This map shows the geographic impact of James D. Phelan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James D. Phelan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James D. Phelan more than expected).

Fields of papers citing papers by James D. Phelan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James D. Phelan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James D. Phelan. The network helps show where James D. Phelan may publish in the future.

Co-authorship network of co-authors of James D. Phelan

This figure shows the co-authorship network connecting the top 25 collaborators of James D. Phelan. A scholar is included among the top collaborators of James D. Phelan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James D. Phelan. James D. Phelan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Xiaohu, Patricia Alfonso, Patrick J. Morris, et al.. (2025). An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors. PubMed Central. 8(12). 4312–4325.

Ren, Min, Peng Li, Kairong Cui, et al.. (2025). BLIMP1 negatively regulates IL-2 signaling in T cells. Science Advances. 11(29). eadx8105–eadx8105. 1 indexed citations

Melani, Christopher, Max J. Gordon, Stefania Pittaluga, et al.. (2024). Abstract PO-008: Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies. Blood Cancer Discovery. 5(3_Supplement). PO–8.

Wright, George W., Julius C. Enßle, Yandan Yang, et al.. (2024). Genetic Subclones Reveal Phenotypic Heterogeneity in Diffuse Large B-Cell Lymphoma. Blood. 144(Supplement 1). 451–451.

Roschewski, Mark, James D. Phelan, & Elaine S. Jaffe. (2024). Primary large B-cell lymphomas of immune-privileged sites. Blood. 144(25). 2593–2603. 15 indexed citations

Dalela, D., Stefania Pittaluga, Jagan Muppidi, et al.. (2023). IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL). Clinical Lymphoma Myeloma & Leukemia. 23. S451–S451. 1 indexed citations

Phelan, James D. & Louis M. Staudt. (2023). Double-headed molecule activates cell-death pathways in cancer cells. Nature. 620(7973). 285–286. 2 indexed citations

Johansen, K., Dominic P. Golec, Bonnie Huang, et al.. (2022). A CRISPR screen targeting PI3K effectors identifies RASA3 as a negative regulator of LFA-1–mediated adhesion in T cells. Science Signaling. 15(743). eabl9169–eabl9169. 15 indexed citations

Huang, Bonnie, James D. Phelan, Silvia Preite, et al.. (2022). In vivo CRISPR screens reveal a HIF-1α-mTOR-network regulates T follicular helper versus Th1 cells. Nature Communications. 13(1). 805–805. 23 indexed citations

10.

Melani, Christopher, Stefania Pittaluga, James D. Phelan, et al.. (2022). Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy. Blood. 140(Supplement 1). 6602–6603. 4 indexed citations

11.

Pittaluga, Stefania, Jagan Muppidi, James D. Phelan, et al.. (2021). Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas. Blood. 138(Supplement 1). 4504–4504. 8 indexed citations

12.

Dersh, Devin, James D. Phelan, Megan E. Gumina, et al.. (2020). Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity. 54(1). 116–131.e10. 85 indexed citations

13.

Roschewski, Mark, James D. Phelan, & Wyndham H. Wilson. (2020). Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. The Cancer Journal. 26(3). 195–205. 27 indexed citations

14.

Kotlov, Nikita, Olga Plotnikova, Krystle Nomie, et al.. (2020). Compromised counterselection by FAS creates an aggressive subtype of germinal center lymphoma. The Journal of Experimental Medicine. 218(3). 20 indexed citations

15.

Webster, Daniel E., Sandrine Roulland, & James D. Phelan. (2019). Protocols for CRISPR-Cas9 Screening in Lymphoma Cell Lines. Methods in molecular biology. 1956. 337–350. 10 indexed citations

16.

Young, Ryan M., James D. Phelan, Arthur L. Shaffer, et al.. (2018). Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy. 3(1). 429–455. 14 indexed citations

17.

Khandanpour, Cyrus, James D. Phelan, Lothar Vaßen, et al.. (2013). Growth Factor Independence 1 Antagonizes a p53-Induced DNA Damage Response Pathway in Lymphoblastic Leukemia. Cancer Cell. 23(2). 200–214. 57 indexed citations

18.

Guo, Fukun, Shuangmin Zhang, Pulak Tripathi, et al.. (2011). Distinct Roles of Cdc42 in Thymopoiesis and Effector and Memory T Cell Differentiation. PLoS ONE. 6(3). e18002–e18002. 40 indexed citations

19.

Phelan, James D. & Susan D. Thompson. (2006). Genomic progress in pediatric arthritis: recent work and future goals. Current Opinion in Rheumatology. 18(5). 482–489. 11 indexed citations

20.

Hopp, Russell J., et al.. (1995). Cross‐sectional study of bone density in asthmatic children. Pediatric Pulmonology. 20(3). 189–192. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact